AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32487881 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perspective on AEs/ASs
Number of subjects: 0
Study 32272284 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 314
Study 32272284 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg stepped up to 300 mg
Number of subjects: 314
Study 32272284 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab 150 mg
Number of subjects: 314
Study 35694107 — intervention group
Group type: EXPERIMENTAL
Intervention: FES+MT training (Functional Electrical Stimulation combined with Mirror Therapy)
Number of subjects: 10
Study 35694107 — intervention group
Group type: COMPARATOR
Intervention: MT training (Mirror Therapy)
Number of subjects: 10
Study 33938678 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐pQLB (0.375% ropivacaine + 100 mcg epinephrine, 20 mL each side)
Number of subjects: 52
Study 33938678 — intervention group
Group type: COMPARATOR
Intervention: pQLB (0.375% ropivacaine alone, 20 mL each side)
Number of subjects: 52
Study 33378772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging with indocyanine green (ICG)
Number of subjects: 7
Study 33378772 — intervention group
Group type: COMPARATOR
Intervention: White light alone
Number of subjects: 7
Study 35574691 — intervention group
Group type: EXPERIMENTAL
Intervention: TQC3564 single ascending dose (SAD) 25 to 1200 mg
Number of subjects: 0
Study 35574691 — intervention group
Group type: EXPERIMENTAL
Intervention: TQC3564 multiple ascending dose (MAD) 100 or 500 mg, QD
Number of subjects: 0
Study 35574691 — intervention group
Group type: EXPERIMENTAL
Intervention: TQC3564 food-effect study 300 mg
Number of subjects: 0
Study 34174090 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) plus hyoscine butylbromide (20 mg)
Number of subjects: 12
Study 32048107 — intervention group
Group type: EXPERIMENTAL
Intervention: bezlotoxumab 10 mg/kg
Number of subjects: 0
Study 32048107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35026861 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 125
Study 35026861 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 125
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose
Number of subjects: 560
Study 33928916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose (0/14 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose (0/14 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0/14 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose (0/28 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose (0/28 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0/28 regimen)
Number of subjects: 560
Study 33928916 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC (both regimens)
Number of subjects: 560
Study 35217898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation
Number of subjects: 19
Study 35217898 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz stimulation
Number of subjects: 19
Study 35217898 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 19
Study 35217898 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Hz stimulation
Number of subjects: 19
Study 35217898 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study 34666273 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral STN-DBS plus optimal drug therapy (ODT)
Number of subjects: 30
Study 34666273 — intervention group
Group type: COMPARATOR
Intervention: optimal drug therapy (ODT) alone
Number of subjects: 30
Study 36296994 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g of fiber/day from 2 buns of 12 g each
Number of subjects: 28
Study 36296994 — intervention group
Group type: COMPARATOR
Intervention: 12 g of fiber/day from 2 buns of 6 g each
Number of subjects: 28
Study 34371825 — intervention group
Group type: EXPERIMENTAL
Intervention: Culinary education through 12 weekly 30-min one-on-one telemedicine culinary coaching sessions
Number of subjects: 28
Study 33153517 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing in intervention practices
Number of subjects: 47000
Study 33153517 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in control practices
Number of subjects: 47000
Study 35685601 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ICU visit prior to patient's admission
Number of subjects: 38
Study 35685601 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 38
Study 34116166 — intervention group
Group type: COMPARATOR
Intervention: Adopted infants (n = 34)
Number of subjects: 147
Study 34116166 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants reared by biological mothers (n = 113)
Number of subjects: 147
Study 34774746 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO–RAP
Number of subjects: 157
Study 34774746 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO
Number of subjects: 157
Study 34774746 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO–RAP (RAP > 8 mm Hg)
Number of subjects: 157
Study 34774746 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO–RAP (RAP ≤ 8 mm Hg)
Number of subjects: 157
Study 33709941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web‐based sexual health literacy intervention
Number of subjects: 781
Study 33709941 — intervention group
Group type: COMPARATOR
Intervention: Single webpage of online information about condom use
Number of subjects: 781
Study 35488875 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 50
Study 35488875 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 50
Study 32919526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Number of subjects: 1073
Study 35180920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular interventional embolization (group A)
Number of subjects: 102
Study 35180920 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy clipping (group B)
Number of subjects: 102
Study 34936266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongtuo Fu's acupuncture
Number of subjects: 150
Study 34936266 — intervention group
Group type: COMPARATOR
Intervention: Tongtuo acupuncture
Number of subjects: 150
Study 34936266 — intervention group
Group type: COMPARATOR
Intervention: Conventional Fu's acupuncture
Number of subjects: 150
Study 35216556 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 44
Study 34128386 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) for 30 minutes
Number of subjects: 0
Study 34128386 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 30 minutes
Number of subjects: 0
Study 34128386 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 33129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 3476
Study 33129989 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 3476
Study 33129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat and Darbepoetin alfa (pooled)
Number of subjects: 3476
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer gambling message condition (experiment 1)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: COMPARATOR
Intervention: Control condition (experiment 1)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow version of gambling message (experiment 2)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: COMPARATOR
Intervention: Control condition (experiment 2)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Black-and-white gambling message condition (experiment 2)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling message condition (experiment 3)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: COMPARATOR
Intervention: Control condition (experiment 3)
Number of subjects: 1509
Study 34784891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based decision aid (DA)
Number of subjects: 130
Study 34784891 — intervention group
Group type: COMPARATOR
Intervention: Usual counselling by family doctor (CG)
Number of subjects: 130
Study 35385794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg orally BID for 12 weeks
Number of subjects: 40
Study 35385794 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 40
Study 34606989 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple self‐collection test kits
Number of subjects: 1048
Study 34606989 — intervention group
Group type: COMPARATOR
Intervention: multiple referrals for standard clinic‐based tests
Number of subjects: 1048
Study 32673356 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp, 320 mgl/ml CM at 4 ml/s (Group B)
Number of subjects: 93
Study 32673356 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp, 320 mgl/ml CM at 5 ml/s (Group C)
Number of subjects: 93
Study 32673356 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp, 400 mgl/ml CM at 4 ml/s (Group A)
Number of subjects: 93
Study 35981780 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in all 3 FU data collection rounds
Number of subjects: 67
Study 35981780 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in FU rounds
Number of subjects: 67
Study 35981780 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination and cardiac assessment participation
Number of subjects: 67
Study 33774741 — intervention group
Group type: EXPERIMENTAL
Intervention: AMOR (Acceptance, Mindfulness, Optimism, Resilience) Method parent group
Number of subjects: 35
Study 33321523 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise training
Number of subjects: 14
Study 33338971 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam (1.5 mg daily for 5 days)
Number of subjects: 60
Study 33338971 — intervention group
Group type: EXPERIMENTAL
Intervention: etifoxine (150 mg daily for 5 days)
Number of subjects: 60
Study 33338971 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 35020462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Transdermal System (d-ATS) 5 mg patch applied for 9 hours
Number of subjects: 0
Study 35020462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Transdermal System (d-ATS)
Number of subjects: 0
Study 35020462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34706706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and home stretching exercises
Number of subjects: 131
Study 34706706 — intervention group
Group type: COMPARATOR
Intervention: Home stretching exercises alone
Number of subjects: 131
Study 32048379 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 6 months
Number of subjects: 116
Study 32048379 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 116
Study 35357316 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based application for lifestyle advice and self-control of risk factors, accessed for 25 weeks.
Number of subjects: 150
Study 35357316 — intervention group
Group type: COMPARATOR
Intervention: Usual care (cardiac rehabilitation only).
Number of subjects: 150
Study 33095213 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramolecular ligand from the drug-candidate library
Number of subjects: 0
Study 32868356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy intervention pathway - rapid point-of-care HCV PCR test and direct-acting antivirals (DAAs) delivered via pharmacist.
Number of subjects: 0
Study 32868356 — intervention group
Group type: COMPARATOR
Intervention: Education-only pathway - counseling on HCV and referral to nurse-led clinic or general practitioner for HCV testing.
Number of subjects: 0
Study 32868356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy intervention pathway
Number of subjects: 0
Study 32868356 — intervention group
Group type: COMPARATOR
Intervention: Education-only pathway
Number of subjects: 0
Study 35840351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (10 ng/kg/min)
Number of subjects: 24
Study 35840351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (15 ng/kg/min)
Number of subjects: 24
Study 35840351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33978823 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus low-dose cytarabine
Number of subjects: 0
Study 33978823 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35233974 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram/memantine (ESC/MEM)
Number of subjects: 26
Study 35233974 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram/placebo (ESC/PBO)
Number of subjects: 26
Study 36002761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 180-µg
Number of subjects: 506
Study 36002761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 120-µg
Number of subjects: 506
Study 36002761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine (all doses pooled)
Number of subjects: 506
Study 36002761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 33369195 — intervention group
Group type: EXPERIMENTAL
Intervention: PRADO-IC transition programme (administrative assistance and nurse follow-up for 2 to 6 months)
Number of subjects: 404
Study 33369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost to avoid a readmission for heart failure within 1 year
Number of subjects: 404
Study 33369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care pathways
Number of subjects: 404
Study 33369195 — intervention group
Group type: EXPERIMENTAL
Intervention: System economic outcomes
Number of subjects: 404
Study 33369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived problems and benefits of the PRADO-IC
Number of subjects: 404
Study 34215599 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C ≥1.8 mmol/L
Number of subjects: 551
Study 34215599 — intervention group
Group type: COMPARATOR
Intervention: LDL-C <1.8 mmol/L
Number of subjects: 551
Study 36205471 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider discussion of genetic counseling (GC)
Number of subjects: 52
Study 32888011 — intervention group
Group type: EXPERIMENTAL
Intervention: Site calculation of anatomical SYNTAX score (SS) based on coronary computed tomography angiography (CTA)
Number of subjects: 223
Study 32888011 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory (CL) calculation of anatomical SYNTAX score (SS) based on coronary computed tomography angiography (CTA)
Number of subjects: 223
Study 32888011 — intervention group
Group type: EXPERIMENTAL
Intervention: Site calculation of functional SYNTAX score (SS) based on coronary CTA and fractional flow reserve derived from computed tomography (FFRCT)
Number of subjects: 223
Study 32888011 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory (CL) calculation of functional SYNTAX score (SS) based on coronary CTA and FFRCT
Number of subjects: 223
Study 32888011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment recommendation based on anatomical SYNTAX score (SS) between sites and CL
Number of subjects: 223
Study 32888011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment recommendation based on functional SYNTAX score (SS) between sites and CL
Number of subjects: 223
Study 32180573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogswell triangular flap modified and transposed
Number of subjects: 0
Study 32180573 — intervention group
Group type: COMPARATOR
Intervention: Cogswell triangular flap
Number of subjects: 0
Study 36177759 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapist-led care (personalized hip therapy)
Number of subjects: 43
Study 36177759 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 43
Study 32776431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self‐testing (HIVST) intervention
Number of subjects: 10111
Study 32776431 — intervention group
Group type: EXPERIMENTAL
Intervention: Current PrEP users
Number of subjects: 10111
Study 32776431 — intervention group
Group type: EXPERIMENTAL
Intervention: Men reporting at least two recent condomless anal intercourse (CAI) partners
Number of subjects: 10111
Study 36321647 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol-Betamethasone Dipropionate (Cal/BD) foam
Number of subjects: 11
Study 36321647 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol-Betamethasone Dipropionate (Cal/BD) foam with AFL
Number of subjects: 11
Study 36321647 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol-Betamethasone Dipropionate (Cal/BD) foam alone
Number of subjects: 11
Study 34272041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel (A + nP)
Number of subjects: 902
Study 34272041 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel (P + nP)
Number of subjects: 902
Study 32465861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 81 mg daily
Number of subjects: 65
Study 32465861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34982718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mole's Veggie Adventures app used at least once a week for 3-4 weeks
Number of subjects: 221
Study 34982718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app intervention)
Number of subjects: 221
Study 34982718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mole's Veggie Adventures app
Number of subjects: 221
Study 33321452 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCELL® administration (putaminal encapsulated porcine choroid plexus cells)
Number of subjects: 18
Study 35018643 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.2 mg/kg)
Number of subjects: 80
Study 35018643 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 80
Study 34062957 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II)
Number of subjects: 30
Study 34062957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE)
Number of subjects: 30
Study 34062957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32615613 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×20 g carbohydrates (muesli bars)
Number of subjects: 24
Study 32615613 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive carbohydrate administration
Number of subjects: 24
Study 32615613 — intervention group
Group type: COMPARATOR
Intervention: No preventive carbohydrates
Number of subjects: 24
Study 32615613 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×10 g carbohydrates (muesli bars)
Number of subjects: 24
Study 37749861 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PRF + SRP
Number of subjects: 26
Study 37749861 — intervention group
Group type: COMPARATOR
Intervention: Saline + SRP
Number of subjects: 26
Study 33249552 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant (OAD)
Number of subjects: 565
Study 33249552 — intervention group
Group type: COMPARATOR
Intervention: Oral antidepressant (OAD) plus placebo nasal spray (PBO)
Number of subjects: 565
Study 32283048 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Therapy (VT) for 8 weeks, approximately 45 minutes twice weekly on the Jintronix Rehabilitation System
Number of subjects: 60
Study 32283048 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 36254909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) technique
Number of subjects: 80
Study 36254909 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 80
Study 33581476 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality (AR) books
Number of subjects: 29
Study 33581476 — intervention group
Group type: COMPARATOR
Intervention: Standard children's book
Number of subjects: 29
Study 32771017 — intervention group
Group type: COMPARATOR
Intervention: Standard approach to scaling-up SNaP
Number of subjects: 6200
Study 32771017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored approach to scaling-up SNaP
Number of subjects: 6200
Study 32920135 — intervention group
Group type: EXPERIMENTAL
Intervention: Andiroba oil (Carapa guianensis Aubl)
Number of subjects: 60
Study 32920135 — intervention group
Group type: COMPARATOR
Intervention: Low power laser
Number of subjects: 60
Study 33218741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Deployment Valves (RDVs)
Number of subjects: 239
Study 33218741 — intervention group
Group type: COMPARATOR
Intervention: Traditional biological valves
Number of subjects: 239
Study 34716201 — intervention group
Group type: EXPERIMENTAL
Intervention: SCO-267, a GPR40 Full Agonist
Number of subjects: 20
Study 34716201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33258102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor and ticagrelor
Number of subjects: 22
Study 33258102 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ticagrelor alone)
Number of subjects: 22
Study 34597783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 34597783 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 33356905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz transcranial alternating current stimulation (10Hz-tACS)
Number of subjects: 0